A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dexamethasone; Floxuridine
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2021 Biomarkers information updated
- 20 Jul 2011 Planned end date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov (NCT00587067).
- 20 Jul 2011 Planned end date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov (NCT00587067).